481 related articles for article (PubMed ID: 18483389)
21. High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors.
Belinsky MG; Skorobogatko YV; Rink L; Pei J; Cai KQ; Vanderveer LA; Riddell D; Merkel E; Tarn C; Eisenberg BL; von Mehren M; Testa JR; Godwin AK
Genes Chromosomes Cancer; 2009 Oct; 48(10):886-96. PubMed ID: 19585585
[TBL] [Abstract][Full Text] [Related]
22. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
Lasota J; Miettinen M
Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological and molecular features of a large cohort of gastrointestinal stromal tumors (GISTs) and review of the literature: BRAF mutations in KIT/PDGFRA wild-type GISTs are rare events.
Huss S; Pasternack H; Ihle MA; Merkelbach-Bruse S; Heitkötter B; Hartmann W; Trautmann M; Gevensleben H; Büttner R; Schildhaus HU; Wardelmann E
Hum Pathol; 2017 Apr; 62():206-214. PubMed ID: 28159677
[TBL] [Abstract][Full Text] [Related]
24. Identifying Secondary Mutations in Chinese Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs) by Next Generation Sequencing (NGS).
Du J; Wang S; Wang R; Wang SY; Han Q; Xu HT; Yang P; Liu Y
Pathol Oncol Res; 2020 Jan; 26(1):91-100. PubMed ID: 31758409
[TBL] [Abstract][Full Text] [Related]
25. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
Corless CL; Schroeder A; Griffith D; Town A; McGreevey L; Harrell P; Shiraga S; Bainbridge T; Morich J; Heinrich MC
J Clin Oncol; 2005 Aug; 23(23):5357-64. PubMed ID: 15928335
[TBL] [Abstract][Full Text] [Related]
26. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del).
Huss S; Künstlinger H; Wardelmann E; Kleine MA; Binot E; Merkelbach-Bruse S; Rüdiger T; Mittler J; Hartmann W; Büttner R; Schildhaus HU
Mod Pathol; 2013 Jul; 26(7):1004-12. PubMed ID: 23599150
[TBL] [Abstract][Full Text] [Related]
27. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
28. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
[TBL] [Abstract][Full Text] [Related]
29. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis.
Miettinen M; Lasota J
Arch Pathol Lab Med; 2006 Oct; 130(10):1466-78. PubMed ID: 17090188
[TBL] [Abstract][Full Text] [Related]
30. A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance.
Boichuk S; Galembikova A; Dunaev P; Valeeva E; Shagimardanova E; Gusev O; Khaiboullina S
Molecules; 2017 Dec; 22(12):. PubMed ID: 29206199
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
32. Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review.
Tan S; Chen P; Ji J; Guo S; Yu D; Asakawa T; Zhou Y; Abe M; Zong L
Dis Markers; 2018; 2018():1368617. PubMed ID: 30224936
[TBL] [Abstract][Full Text] [Related]
33. Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction.
Nannini M; Astolfi A; Paterini P; Urbini M; Santini D; Catena F; Indio V; Casadio R; Pinna AD; Biasco G; Pantaleo MA
Future Oncol; 2013 Jan; 9(1):121-6. PubMed ID: 23252569
[TBL] [Abstract][Full Text] [Related]
34. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated.
Penzel R; Aulmann S; Moock M; Schwarzbach M; Rieker RJ; Mechtersheimer G
J Clin Pathol; 2005 Jun; 58(6):634-9. PubMed ID: 15917417
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic and molecular genetic study of 22 Korean cases.
Kang G; Park YS; Jung ES; Joo M; Kang MS; Ahn S; Kang GH; Kim KM
APMIS; 2013 Oct; 121(10):938-44. PubMed ID: 23755839
[TBL] [Abstract][Full Text] [Related]
36. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Guo T; Agaram NP; Wong GC; Hom G; D'Adamo D; Maki RG; Schwartz GK; Veach D; Clarkson BD; Singer S; DeMatteo RP; Besmer P; Antonescu CR
Clin Cancer Res; 2007 Aug; 13(16):4874-81. PubMed ID: 17699867
[TBL] [Abstract][Full Text] [Related]
37. [c-kit and PDGFRA mutations in 60 cases of gastrointestinal stromal tumors (GISTs)].
He HY; Xiang YN; Li Y; Zhong HH; Wu BQ; Zheng J
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):320-4. PubMed ID: 15968329
[TBL] [Abstract][Full Text] [Related]
38. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
Reichardt P; Demetri GD; Gelderblom H; Rutkowski P; Im SA; Gupta S; Kang YK; Schöffski P; Schuette J; Soulières D; Blay JY; Goldstein D; Fly K; Huang X; Corsaro M; Lechuga MJ; Martini JF; Heinrich MC
BMC Cancer; 2016 Jan; 16():22. PubMed ID: 26772734
[TBL] [Abstract][Full Text] [Related]
39. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Boikos SA; Pappo AS; Killian JK; LaQuaglia MP; Weldon CB; George S; Trent JC; von Mehren M; Wright JA; Schiffman JD; Raygada M; Pacak K; Meltzer PS; Miettinen MM; Stratakis C; Janeway KA; Helman LJ
JAMA Oncol; 2016 Jul; 2(7):922-8. PubMed ID: 27011036
[TBL] [Abstract][Full Text] [Related]
40. The activated targets of mTOR signaling pathway are characteristic for PDGFRA mutant and wild-type rather than KIT mutant GISTs.
Sápi Z; Füle T; Hajdu M; Matolcsy A; Moskovszky L; Márk A; Sebestyén A; Bodoky G
Diagn Mol Pathol; 2011 Mar; 20(1):22-33. PubMed ID: 21326036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]